Yes, Aricept (donepezil) can be combined with some dementia treatments, most clearly memantine for moderate-to-severe Alzheimer's dementia. It should not be casually combined with another cholinesterase inhibitor, and every add-on requires clinician review. Aricept is specifically labeled for mild, moderate, and severe dementia of the Alzheimer's type. It is not a general treatment for every cause of dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When does the diagnosis and stage matter?
- How strong is the evidence for adding memantine?
- Which dementia drugs should not simply be stacked?
- What about donanemab?
- What should families review before another treatment is added?
When does the diagnosis and stage matter?
The Aricept prescribing information on DailyMed limits its indication to Alzheimer's dementia. A person's exact diagnosis therefore matters before Aricept is started or combined with another treatment. Disease stage also affects the choice.
An FDA-labeled fixed-dose memantine-and-donepezil product is indicated for moderate-to-severe Alzheimer's dementia in people stabilized on 10 mg of donepezil daily, according to DailyMed's combination-product label. That does not mean everyone taking Aricept should add memantine. The documented combination applies to a defined diagnosis, stage, and donepezil dose.
How strong is the evidence for adding memantine?
A 24-week randomized trial included 404 people with moderate-to-severe Alzheimer's disease who were already taking stable donepezil. Adding memantine produced better cognition, daily-function, global, and behavioral results than adding placebo, according to the JAMA trial indexed by the National Library of Medicine. On a 100-point cognition scale, the memantine group changed by 0.9 points, compared with a 2.5-point decline in the placebo group. Daily-function scores declined by 2.0 and 3.4 points, respectively.
These are group averages, not a guarantee that an individual will noticeably improve. The evidence is mixed over longer periods. In the 52-week DOMINO trial, adding memantine to continued donepezil was not significantly better than donepezil alone on primary or secondary outcomes, as reported in the New England Journal of Medicine. The combination is an established option, but its added benefit is not equally clear in every study.
Which dementia drugs should not simply be stacked?
Rivastigmine and galantamine belong to the same cholinesterase-inhibitor category as donepezil. Aricept's label warns that combining it with other cholinesterase-increasing drugs may produce synergistic cholinergic effects. This makes unsupervised layering different from adding memantine.
A prescriber should decide whether another cholinesterase inhibitor is meant to replace Aricept rather than accompany it. Donepezil may also counteract medicines with anticholinergic effects. A complete medication review should include prescription drugs and over-the-counter products, not just treatments identified as dementia medicines.
What about donanemab?
The FDA's 2025 Kisunla label reports that donanemab trials allowed participants with early Alzheimer's disease to continue cholinesterase inhibitors or memantine. This shows that concurrent use occurred in the trials.
It does not establish that adding Aricept makes donanemab more effective than donanemab alone. It also should not be confused with the donepezil-memantine evidence, which concerns moderate-to-severe Alzheimer's dementia rather than early disease.
What should families review before another treatment is added?
Donepezil can cause slow heart rate, heart block, fainting, gastrointestinal symptoms, and weight loss. Those risks make the person's current symptoms and complete medication list important when considering any additional treatment.
Before the prescribing visit, write down: Do not start a second cholinesterase inhibitor or add memantine independently. Ask the prescriber to confirm that the diagnosis, disease stage, current dose, and interaction risks fit the proposed combination.
- The exact dementia diagnosis and stage.
- The current Aricept dose and how long it has been stable.
- Every prescription and over-the-counter medicine being used.
- Any fainting, digestive symptoms, weight loss, or known slow heart rate.
- The specific benefit expected from the new treatment and how it will be assessed.
